Online citations, reference lists, and bibliographies.
← Back to Search

Treatment, Outcome, And Cost Of Care In Children With Idiopathic Thrombocytopenic Purpura

Manjusha Kumar, T. Vik, Cynthia S. Johnson, M. Southwood, J. Croop
Published 2005 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Data were reviewed on treatment patterns, outcome, and hospital charges for children with idiopathic thrombocytopenic purpura (ITP). Records of 186 children with ITP, seen between January 1997 and April 2001, were reviewed. Hospital charges for initial management and first re‐treatment were calculated by combining physician, hospital, and pathology charges. Anti‐D immune globulin [anti‐D IG] was used in 32.3%, intravenous immune globulin [IVIG] in 22.6%, steroids in 22.6%, combination therapies in 8%, and 14.5% were observed. Two patients had CNS bleeding, one with intraventricular hemorrhage at diagnosis, and the other with a parietal bleed 1 year from diagnosis. There was no significant differences in time to reach platelet counts of 20, 50, or 150 (×109/L) across different treatment groups. There was no significant difference in median charges for the IVIG and anti‐D IG groups for the initial treatment of ITP. However, the IVIG was significantly more expensive than steroids or observation. Charges for the anti‐D IG group were higher than the observation group but not the steroid group. After drug charges were excluded, patients in the IVIG group had statistically higher charges compared to patients in anti‐D IG group. Almost half the patients were re‐treated. There was no significant difference between anti‐D IG, IVIG, and steroid groups when initial and re‐treatment charges were combined. The observation group remained least expensive. Outcome for children with ITP is similar regardless of initial management. There is not a statistically significant difference in hospital charges between patients treated with anti‐D IG and IVIG. The IVIG‐treated group tends to be more costly, but this is not due to drug charges. Re‐treatment is common and decreases the difference in patient charges among initial therapies. Am. J. Hematol. 78:181–187, 2005. © 2005 Wiley‐Liss, Inc.
This paper references
10.2307/2063815
Nonparametric Statistical Methods
M. Hollander (1973)
10.1016/S0022-3476(85)80231-6
Treatment of acute idiopathic thrombocytopenia of childhood with intravenous infusions of gammaglobulin.
J. Bussel (1985)
10.1016/S0140-6736(85)90400-3
INTRAVENOUS IMMUNOGLOBULIN VERSUS ORAL CORTICOSTEROIDS IN ACUTE IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDHOOD
P. Imbach (1985)
10.1136/adc.67.8.1056
Guidelines for management of idiopathic thrombocytopenic purpura. The British Paediatric Haematology Group.
O. Eden (1992)
10.1016/S0140-6736(94)92205-5
Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura
V. Blanchette (1994)
10.1111/j.1651-2227.1996.tb14183.x
Randomized trial comparing intravenous immunoglobulin with methylprednisolone pulse therapy in acute idiopathic thrombocytopenic purpura
S. Rosthøj (1996)
10.1182/BLOOD.V88.1.3.BLOODJOURNAL8813
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.
J. George (1996)
10.1016/s0887-7963(97)80114-9
Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients.
A. Scaradavou (1997)
10.1016/S0140-6736(97)04143-3
Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines
P. Bolton-Maggs (1997)
10.1016/S0022-3476(98)70265-3
Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome.
D. Medeiros (1998)
Idiopathic thrombocytopenia purpura: Treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy.
K. Simpson (1998)
10.1016/S0022-3476(99)70367-7
Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin.
M. Tarantino (1999)
10.1080/08880010050122816
IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDHOOD IN NORWAY: A Prospective, Population-Based Registration
B. Zeller (2000)
10.1097/00043426-200001000-00011
Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology/oncology specialists.
S. Vesely (2000)
10.3324/%X
Acute childhood idiopathic thrombocytopenic purpura: AIEOP consensus guidelines for diagnosis and treatment. Associazione Italiana di Ematologia e Oncologia Pediatrica.
D. De Mattia (2000)
10.1067/MPD.2000.110123
The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment.
R. Dickerhoff (2000)
10.3324/%X
Anti-D immunoglobulin in children with newly diagnosed immune thrombocytopenic purpura: a pilot study.
P. Monteleone (2000)
A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura.
K. Fujisawa (2000)
10.1002/(SICI)1096-8652(200003)63:3<156::AID-AJH9>3.0.CO;2-4
The cost of treating immune thrombocytopenic purpura using intravenous Rh immune globulin versus intravenous immune globulin
S. G. Sandler (2000)
10.1016/S0140-6736(01)07219-1
Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study
T. Kühne (2001)
10.1046/j.1365-2141.2001.02627.x
A dose of 75 μg/kg/d of i.v. anti‐D increases the platelet count more rapidly and for a longer period of time than 50 μg/kg/d in adults with immune thrombocytopenic purpura
G. Newman (2001)
10.1097/00043426-200210000-00008
Randomized Trial of High-Dose Methylprednisolone Versus Intravenous Immunoglobulin for the Treatment of Acute Idiopathic Thrombocytopenic Purpura in Children
K. G. Ancona (2002)
10.1097/00043426-200302000-00009
Self-Reported Initial Management of Childhood Idiopathic Thrombocytopenic Purpura: Results of a Survey of Members of the American Society of Pediatric Hematology/Oncology, 2001
S. Vesely (2003)
10.1046/j.1365-2141.2003.04131.x
Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy
D. Provan (2003)



This paper is referenced by
10.1182/bloodadvances.2019000966
American Society of Hematology 2019 guidelines for immune thrombocytopenia.
C. Neunert (2019)
Clinical Practice Updates in the Management Of Immune Thrombocytopenia.
Ayesha M. Khan (2017)
Table 3 First-Line Treatment Options for Immune Thrombocytopenia
Ayesha M. Khan (2017)
Comparison of Anti-D Immunoglobulin and Dexamethasone in Chronic and Persistent Forms of Pediatric Immune Thrombocytopenic Purpura
H. Farhangi (2016)
10.1001/jamapediatrics.2014.2214
Influence of the American Society of Hematology guidelines on the management of newly diagnosed childhood immune thrombocytopenia.
Corinna L Schultz (2014)
10.1007/s11239-012-0801-z
Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura
Muhittin Çelik (2012)
Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.
G. Blackhouse (2012)
10.4274/TPA.1659
2011 yılında çocukluk çağı immün trombositopenik purpura hastalığı izlem ve tedavisinde değişiklikler
T. Celkan (2012)
10.1007/S13312-010-0093-3
Efficacy and safety of anti-D for immune thrombocytopenic purpura in children
R. Naithani (2010)
Canadian Agency for Drugs and Technologies in Health Intravenous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy : Clinical-and Cost-Effectiveness Analyses
K. Gaebel (2009)
10.1002/pbc.21916
Comparison of idiopathic thrombocytopenic purpura in children between 3 months and 2 years versus 2–5 years
D. Kalyoncu (2009)
10.26719/2009.15.3.729
Immune thrombocytopenia in children with reference to low-income countries.
A. Rehman (2009)
Canadian Agency for Drugs and Technologies in Health Intravenous Immunoglobulin for Treatment of Idiopathic Thrombocytopenic Purpura : Economic and Health Service Impact Analyses
G. Blackhouse (2008)
10.1007/s12098-008-0243-y
Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura
E. Shahgholi (2008)
10.1177/147323000803600324
Cost-effectiveness of Treatment for Acute Childhood Idiopathic Thrombocytopenic Purpura (ITP) – a Systematic Review
M. Chen (2008)
10.1159/000112837
Management of Acute Childhood Idiopathic Thrombocytopenic Purpura according to AIEOP Consensus Guidelines: Assessment of Italian Experience
G. C. Del Vecchio (2008)
10.1016/J.HOC.2007.06.007
Immune thrombocytopenic purpura.
B. Psaila (2007)
Acute immune thrombocytopenic purpura in children.
A. Rehman (2007)
Evaluation of clinical characteristics, diagnosis and management in childhood immune thrombocytopenic purpura: a single center's experience.
U. Koçak (2007)
10.1002/pbc.20830
A cost‐utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP)
Sarah H. O'Brien (2007)
10.1002/pbc.20996
A review of anti‐D treatment of childhood idiopathic thrombocytopenic purpura
Mimi Kjaersgaard (2006)
10.1002/pbc.20968
Current challenges in the management of children with idiopathic thrombocytopenic purpura
G. Buchanan (2006)
10.2165/00148581-200507050-00004
Treatment of Immune Thrombocytopenic Purpura in Children
A. Shad (2005)
Changes in chilhood ITP treatment and follow-up in 2011
T. Celkan ()
Semantic Scholar Logo Some data provided by SemanticScholar